Bone drug may supercharge immunotherapy against tough melanoma
NCT ID NCT03620019
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding denosumab (a bone-strengthening drug) to standard immunotherapy (pembrolizumab or nivolumab) could help control advanced melanoma that has spread. Researchers enrolled 25 adults with stage III or IV melanoma who had not received prior immunotherapy. They measured changes in immune cells in blood and tumor samples to see if the combination boosted the body's attack on cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dartmouth-Hitchcock Medical Center
Manchester, New Hampshire, 03104, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- E-Learning could sharpen Doctors' eye for skin cancer
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a new drug tame advanced solid tumors?
- Can a One-Two punch of immune boosters revive cancer treatment?